Guardant Health Announces Additions to Leadership Team
08 Maio 2023 - 5:05PM
Business Wire
- Ines Dahne-Steuber named as chief operating officer
- Darya Chudova promoted to chief technology officer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced the expansion of its leadership team with
the addition of Ines Dahne-Steuber as chief operating officer and
the promotion of Darya Chudova to chief technology officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230508005605/en/
Ines Dahne-Steuber, Chief Operating
Officer (Photo: Busines Wire)
“At Guardant, we have built one of the most transformative
platforms in diagnostics and we think extensively about how we get
work done more efficiently, from development through delivery, to
fulfill our primary mission of helping patients,” said Helmy
Eltoukhy, Guardant Health chairman and co-CEO. “As we scale our
global operations, with an eye toward future product launches, Ines
and Darya are uniquely qualified to help us succeed in this next
exciting chapter of our journey.”
Ines Dahne-Steuber brings over 20 years of leadership and
strategic expertise in healthcare operations. Prior to joining
Guardant Health, she served as senior vice president of operational
excellence and president of Spectra Laboratories at Fresenius
Medical Care North America. Spectra Laboratories performs 100
million clinical and environmental tests serving over 200,000
dialysis patients per year. Prior to Fresenius Medical Care, she
served in various leadership roles at Quest Diagnostics, most
recently as general manager for oncology and vice president of
healthcare IT solutions. Ms. Dahne-Steuber earned her Bachelor of
Arts and Master’s degrees at Humboldt University in Berlin,
Germany.
Darya Chudova has been with Guardant Health for eight years,
most recently serving as the senior vice president of technology.
In this role, she initially focused on leading technical
development of Guardant360 LDT and CDx products improving the
precision, robustness and accessibility of Guardant’s liquid biopsy
tests. Most recently, she has led the development of Guardant’s
ShieldTM technology for blood-based colorectal cancer screening,
which is currently under review with the U.S. Food and Drug
Administration. Prior to Guardant, Darya successfully developed
tools for clinical diagnostics and interpretation of genomic
expression and sequencing data in the context of molecular cytology
at Veracyte, Inc. and non-invasive prenatal testing at Illumina,
Inc. Ms. Chudova holds a Doctor of Philosophy degree from UC
Irvine.
“We are very pleased to welcome Ines to Guardant’s leadership
team. She brings a wealth of knowledge and operational expertise of
lab operations,” said AmirAli Talasaz, co-CEO. “Darya has already
been instrumental in our technology development over the last eight
years. With the newly created role of chief technology officer, we
are combining our research and development efforts across oncology
and screening, and leveraging our single platform across multiple
products to allow us to scale more efficiently. The leadership of
both Ines and Darya will be extremely valuable as we continue to
further improve our ability to operate effectively while balancing
our need to innovate at pace.”
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY™ tests for advanced-stage cancer, and Guardant
Reveal™ for early-stage cancer. The Guardant Health screening
portfolio, including the Shield™ test, aims to address the needs of
individuals eligible for cancer screening. For more information,
visit guardanthealth.com and follow the company on LinkedIn and
Twitter.
Source: Guardant Health, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230508005605/en/
Investor Contact: Alex Kleban
investors@guardanthealth.com +1 657-254-5417
Media Contact: Michael Weist press@guardanthealth.com +1
317-371-0035
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024